Choose Your Country or Region

Bevacizumab (anti-VEGF)

Synonyms: rhuMab VEGF

Catalog No.A2006 Purity:98.95%

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Click to purchase the isotype control of Bevacizumab (anti-VEGF)

Selleck's Bevacizumab (anti-VEGF) has been cited by 45 publications

Purity & Quality Control

Batch: Purity: 98.95% Protein concentration: 4.94mg/ml Endotoxin Level: ≤1 EU/mg

98.95

Choose Selective VEGFR Inhibitors

Name	Citation	VEGFR1	VEGFR2	VEGFR3	VEGFR	VEGF	Others
Foretinib	93	+++	++++	++++			Met,Tie-2,RON
Cediranib (AZD2171)	67	+++	++++	++++			c-Kit,PDGFRβ,FGFR1
PD173074	123		+				FGFR1
Dovitinib (TKI-258)	51	+++	++	+++			FLT3,c-Kit,FGFR1
Linifanib (ABT-869)	33	++++	++++	+			CSF-1R,FLT3,Kit
Vatalanib (PTK787) 2HCl	52	+	+	+			PDGFRβ,c-Kit,c-Fms
RAF265 (CHIR-265)	23		++				B-Raf
Motesanib Diphosphate (AMG-706)	12	++++	++++	+++			Kit,RET,PDGFR
Brivanib (BMS-540215)	10	+	++				FGFR1
MGCD-265 analog	12	++++	++++	++++			Met,RON,Tie-2
AEE788 (NVP-AEE788)	13	+	+				EGFR,HER2/ErbB2,c-Abl
ENMD-2076	9		+	++			FLT3,RET,Aurora A
OSI-930	7	+++	+++				CSF-1R,LCK,C-Raf
CYC116	10		+				Aurora A,Aurora B,FLT3
Ki8751	21		++++				c-Kit,PDGFRα
Telatinib	5		+++	++++			c-Kit,PDGFRα
PP121	5		+++				PDGFR,Hck,mTOR
KRN 633	6	+	+	+			PDGFRα,c-Kit,BTK
SAR131675	32			++
Apatinib (YN968D1) mesylate	24		++++				RET
BMS-794833	1		++				Met
Brivanib Alaninate (BMS-582664)	2	+	++				FGFR1
Golvatinib (E7050)	8		++				c-Met
Semaxanib (SU5416)	20		+
ZM 323881 HCl	19		++++
ZM 306416	13	+					Src,Abl
R1530	0		+++				FGFR1
Chiauranib	0		+++				c-Kit,CSF-1R,Aurora B
Emvododstat (PTC299)	0					++++	Dihydroorotate dehydrogenase
XL092	0		++++				AXL,MER,MET
Lucitanib (E3810) hydrochloride	1	+++	++	+++			FGFR1,FGFR2
Ningetinib	0		++++				Axl,c-Met
Ki20227	1		+++				c-Fms,PDGFRβ,c-Kit
Tyrphostin AG1433	0		+				PDGFRβ
SU14813	2	++++	+				PDGFRβ,KIT
Sulfatinib	1	++++	++	++++			CSF1R,FGFR1
CS-2660 (JNJ-38158471)	0		+				RET,Kit
SU5204	1		+				HER2
SU5214	0		+				EGFR
SU5205	0		+
SU5408	2		+
Pamufetinib (TAS-115)	0		++				recombinant MET
ODM-203	0	++	+++	+++			FGFR3,FGFR1,FGFR2
WHI-P180	0		+				RET
Altiratinib	2		+++				MET Y1230C,TrkA,TrkC
Motesanib (AMG-706)	11	++++	++++	+++			c-Kit,c-Ret,PDGFR
Fruquintinib	4	++	++	++++
Apatinib	26		++++				RET
Cediranib Maleate	14	+++	++++	++++			c-Kit,PDGFRβ,FGFR1
Toceranib phosphate	1		+++				PDGFR
Anlotinib (AL3818) dihydrochloride	41		++++	++++			c-Kit
Sitravatinib (MGCD516)	4	+++	+++	++++			DDR2,EPHA3,Axl
BFH772	0		++++
BAW2881 (NVP-BAW2881)	2	+	+++	+			C-Raf-1,B-RAFV599E,c-Abl
SU5402	20		++				FGFR1,PDGFRβ
Dovitinib (TKI258) Lactate monohydrate	31	+++	++	+++			FLT3,c-Kit,FGFR1
LY2874455	14		+++				FGFR2,FGFR1,FGFR4
SKLB1002	5		++
AZD2932	3		+++				PDGFRβ,Flt3,c-Kit
WAY-340935		✔
hVEGF-IN-1					✔
4SC-203				✔
Chebulinic acid				✔
Nastorazepide				✔
Vorolanib				✔		PDGFR
MAZ51			✔			RhoA,GSK3β,Akt
SU5208		✔
SU5614		✔				FLT3,c-Kit,RET
AG-13958				✔
SKLB 610		✔				FGFR2,PDGFR
SU1498		✔
ZD-4190		✔				Flt-1
PDGFR inhibitor 1		✔				PDGFR,Kit,c-Fms
Taxifolin (Dihydroquercetin)		✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Features

Human IgG1

Targets

VEGFR2 ^[4]

VEGF-A ^[4]

VEGF ^[1]

In Vitro
In vitro	Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.^[1]
Cell Research:	Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.

In Vitro

In vitro

Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.^[1]

Cell Research:

Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.

In Vivo
In vivo	The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.^[2]
Animal Research	Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model Dosages: 2 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/

References
[1] Hurley-Novatny AC, et al. J Invest Dermatol. 2022 Feb 19:S0022-202X(22)00125-7. [2] Lin Y, et al. Hepatology. 2021 Dec 23.

References

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	216974-75-3
Isotype	Human IgG1
Source	CHO cells
Formulation	PBS buffer, pH 7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.